Here’s What Analysts Are Saying About Grail Inc. (GRAL)

Grail Inc. (NASDAQ:GRAL) is one of the best small-cap stocks with huge growth potential. On February 20, Baird cut the price target on Grail Inc. (NASDAQ:GRAL) to $82 from $113 while maintaining an Outperform rating on the shares. The rating update came after the announcement that its NHS study missed its primary endpoint.

A healthcare professional wearing a health communications device discussing patient data with a colleague.

The same day, Canaccord also cut the price target on Grail Inc. (NASDAQ:GRAL) to $80 from $105 while maintaining a Buy rating on the shares. The firm told investors that although it is disappointed with the company’s NHS-Galleri top-line results and acknowledges that the path forward may be less certain, it still believes that the after-hours selloff, nearly 50%, is an overreaction. It thus remains confident in the NHS Galleri results despite missing the primary endpoint.

The rating updates came after Grail Inc. (NASDAQ:GRAL) reported its fiscal Q4 and full year 2025 results on February 19, with the total revenue in fiscal Q4 growing 14% year-over-year to $43.6 million and the U.S. Galleri revenue growing 31% year over year to $41.3 million. Total revenue for the full year rose 17% year over year to $147.2 million, while the U.S. Galleri revenue grew 26% year over year to $136.8 million.

Grail Inc. (NASDAQ:GRAL) is a commercial-stage healthcare company that develops a technology for the early detection of cancer. The company employs software, machine learning, and automation for the identification and detection of multiple deadly cancer types in earlier stages.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.